We found that a level of CD3+ lymphocytes in the center of the tumor was significantly higher in patients with low pre-treatment NLR; however, no correlation between any of the pre-treatment blood-based markers and CD3+ or CD8+ lymphocytes in the resected tumor was demonstrated. The gene discussed is CD8A; the disease is neoplasm.